Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study

被引：80

作者：

Bergenstal, Richard M. ^{[1
]}

Tamborlane, William V. ^{[2
]}

Ahmann, Andrew ^{[3
]}

Buse, John B. ^{[4
]}

Dailey, George ^{[5
]}

Davis, Stephen N. ^{[6
]}

Joyce, Carol ^{[7
]}

Perkins, Bruce A. ^{[8
]}

Welsh, John B. ^{[9
]}

Willi, Steven M. ^{[10
]}

Wood, Michael A. ^{[11
]}

机构：

[1] Int Diabet Ctr Pk Nicollet, Minneapolis, MN USA

[2] Yale Univ, Sch Med, Yale Ctr Clin Invest, New Haven, CT USA

[3] Oregon Hlth & Sci Univ, Harold Schnitzer Diabet Hlth Ctr, Portland, OR 97201 USA

[4] Univ N Carolina, Sch Med, Dept Med, Div Endocrinol, Chapel Hill, NC USA

[5] Scripps Res Inst, Div Diabet & Endocrinol, La Jolla, CA USA

[6] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA

[7] Mem Univ Newfoundland, Dept Med, St Johns Hlth Sci Ctr, St John, NF, Canada

[8] Univ Toronto, Dept Med, Div Endocrinol, Sch Med, Toronto, ON, Canada

[9] Medtronic Inc, Northridge, CA USA

[10] Childrens Hosp Philadelphia, Diabet Ctr Children, Philadelphia, PA 19104 USA

[11] Helen DeVos Childrens Hosp, Div Pediat Endocrinol, Grand Rapids, MI USA

来源：

DIABETES CARE | 2011年 / 34卷 / 11期

关键词：

D O I：

10.2337/dc11-1248

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

OBJECTIVE-To examine the effects of crossing over from optimized multiple daily injection (MDI) therapy to sensor-augmented pump (SAP) therapy for 6 months, and the effects of 18 months' sustained use of SAP. RESEARCH DESIGN AND METHODS-The 6-month, single-crossover continuation phase of Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) provided SAP therapy to 420 subjects who completed the 1-year randomized study. The primary outcome was change in A1C in the crossover group. RESULTS-A1C values were initially lower in the continuing-SAP group than in the crossover group (7.4 vs. 8.0%, P < 0.001). A1C values remained reduced in the SAP group. After 3 months on the SAP system, A1C decreased to 7.6% in the crossover group (P < 0.001); this was a significant and sustained decrease among both adults and children (P < 0.05). CONCLUSIONS-Switching from optimized MDI to SAP therapy allowed for rapid and safe A1C reductions. Glycemic benefits of SAP therapy persist for at least 18 months.

引用

页码：2403 / 2405

页数：3

共 7 条

[1]

Agrawal Pratik, 2011, J Diabetes Sci Technol, V5, P1137

[2]

[Anonymous], PEDIAT DIABETES 0703

[3] Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes [J].